

Please amend the above-identified application as follows:

IN THE CLAIMS:

Please cancel claims 77-89 and 146-147 drawn to a non-elected invention in accordance with the Restriction Requirement Paper No. 10, without prejudice. Applicants note for the record that they do not accede to the merits of the Restriction Requirement, which are rendered moot by the election made by Applicants in Paper No. 11. Applicants reserve the right to prosecute the subject matter of the cancelled claims and all other subject matter supported by the specification in a related application.

Please amend claims 117 and 122-124 as follows:

117. (Amended) A method for eliciting an immune response in a mammalian subject directed against respiratory syncytial virus, which comprises administering to the subject an immunologically sufficient amount of the isolated attenuated recombinant RSV of claim 63.

122. (Amended) An immunogenic composition effective to elicit an immune response directed against RSV, which comprises an immunologically sufficient amount of the isolated attenuated recombinant RSV of claim 63 in a physiologically acceptable carrier.

123. (Amended) The immunogenic composition of claim 122, formulated in a dose of 10^3 to 10^6 PFU of the attenuated RSV.

124. (Amended) The immunogenic composition of claim 122, formulated for administration to the upper respiratory tract by spray, droplet or aerosol.